Discover investment opportunities in Best Biotech Stocks 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Biotech Stocks 2024 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Biotech Stocks 2024 using our Smart AI Filter.
9 stocks found for "Best Biotech Stocks 2024"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.34 | ±25.2% | 8.0 | 0.00% | |||
0.70 | ±46.8% | 1.5 | 0.00% | |||
1.34 | ±55.5% | -10.4 | 0.00% | |||
0.30 | ±26.0% | 12.1 | 0.66% | |||
0.36 | ±26.9% | 24.5 | 0.00% | |||
0.83 | ±70.5% | -3.5 | 0.00% | |||
0.45 | ±25.0% | 14.4 | 3.19% | |||
1.19 | ±53.7% | -156.9 | 0.00% | |||
0.22 | ±27.3% | 15.0 | 2.83% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: Why do investors consider Vertex Pharmaceuticals (VRTX) a strong growth stock in the biotech sector?
A: Vertex Pharmaceuticals (VRTX) is often seen as a strong growth stock due to its leading position in the cystic fibrosis market and promising pipeline in gene editing and cell therapies. The company has demonstrated solid revenue growth and profit margins, which suggests potential for continued expansion.
Q: What are the dividend prospects for Amgen (AMGN) in 2024?
A: Amgen (AMGN) is known for providing dividends, appealing to income-focused investors. With a consistent history of dividend payments and increases, it may continue to be a solid choice for dividend yield, contingent on the company's financial health and market conditions.
Q: How does Moderna's (MRNA) focus on mRNA technology impact its stock volatility?
A: Moderna (MRNA) is highly focused on mRNA technology, which can lead to volatility due to the speculative nature and emerging competition in this field. While mRNA technology offers substantial innovation potential, it is crucial for investors to monitor regulatory and competitive developments.
Q: What are the ESG (Environmental, Social, and Governance) considerations for investing in Biogen (BIIB)?
A: Biogen (BIIB) has made commitments to sustainability and governance practices. Investors interested in ESG factors may examine its policies on clinical trial ethics, diversity, and environmental impact while considering the challenges it faces in regulatory compliance and drug pricing issues.
Q: How do economic cycles affect Regeneron Pharmaceuticals (REGN)?
A: Regeneron Pharmaceuticals (REGN) has shown resilience during varying economic conditions due to its robust product portfolio, including treatments for chronic conditions. However, economic downturns could impact funding for healthcare innovation and investment.
Q: Is Gilead Sciences (GILD) a value stock for 2024?
A: Gilead Sciences (GILD) may attract value investors due to its historically low price-to-earnings ratio and stable revenue from antiviral products. However, competition and patent expirations must be considered as they can affect long-term valuation metrics.